As a highly esteemed Wall Street venture capitalist, Dr. Lindsay Rosenwald possesses a brilliant reputation that spans almost two decades. His expertise in life-sciences research in various fields is well known among his peers. Dr. Rosenwald leads the way in the areas of innovative R&D within the biotechnology and healthcare industries. Dr. Rosenwald enjoys a unique ability to discover prospective investment opportunities and his contributions in these areas have expanded the vistas of healthcare investing. His achievements in these fields are monumental.

Over the course of his career, Dr. Lindsay A. Rosenwald has created and re-capitalized numerous private and public companies within the biotechnology sector, as well as the life-sciences field.

Dr. Lindsay A. Rosenwald earned his degree in finance at the Pennsylvania State University. Attending the Temple University School of Medicine, he received his MD, later completing his internship at Abington Medical Hospital located in Abington, Pennsylvania.

From 1994 to 2007, Dr. Lindsay A. Rosenwald served as the executive director of Aries Real Estate Fund, which has invested over $1 billion in promising healthcare businesses. As head of the Orion Fund from 2002 to 2006, Dr. Rosenwald invested in biotechnology, focusing on private investments in public equity.

Today, Dr. Rosenwald serves as a director of the Republican Jewish Coalition; he is president of Paramount Group as well, a company, which specializes in investment banking. The Paramount Group also invests in equity management, and research and development, focusing mostly on the biotechnology industry as well as the life-sciences industry.

A recent undertaking for Dr. Lindsay A. Rosenwald, OpusPoint Partners, LLC was founded in 2009 with the purpose of creating and promoting cutting-edge technologies and supporting new achievements in this very specialized industry.

Among the greatest accomplishments of Dr. Lindsay Rosenwald and his staff are the funding of companies like Cougar Biotechnology Inc. Cougar Biotechnology is working on a number of promising cancer treatment drugs. One drug in particular, Abiraterone, treats the most aggressive strains of prostate cancer and shows great promise for future development.

Dr. Rosenwald is president of the Rosenwald Foundation, a non-profit organization based in New York that supports various healthcare, scientific, and educational establishments.

Founded in 2009 by Michael S. Weiss and Dr. Lindsay Rosenwald, OpusPoint Partners is only one of a group of biotech companies created by these two men. Both Weiss and Rosenwald are zealous adherents to the biotechnology world. The two of them together have over 40 years in experience with life science and biotech investing.

Dr. Lindsay Rosenwald is also the founder of another company named Cougar Biotechnology Inc., a Los Angeles-based company which does research on experimental cancer drugs. Researchers and investors have been following Cougar’s progress as the company turns out some exciting products with great potential. A drug in Cougar’s portfolio may have an impact on prostate cancer late-stage treatment. Johnson & Johnson purchased Cougar Biotech Labs on July 10, 2009 for around one billion dollars.

Lindsay Rosenwald and OpusPoint Partners are particularly interested in building sturdy business alliances with the investment and biotechnology communities. Conducting honest investment and open disclosure policies maintains integrity in the relationships and is also forms an organization’s culture of ethics. These practices create strong relationships when observed by all business and industry partners.

OpusPoint Partners and Lindsay Rosenwald are making alliances with several people, research groups, investors and corporations in an attempt to make large strides in medical innovations that will improve disease treatment. They will also help start-up companies to acquire their goals. With the strength of these relationships, Dr. Lindsay Rosenwald and OpusPoint Partners intend to find, and invest in, the most promising research companies on the verge of very big discoveries.

Dr. Lindsay Rosenwald and OpusPoint Partners are taking biotech investment in a new direction. They are encouraging biotech facilities to enforce a morally-sound set of ideals and really sound business practices, in essence to raise the standards of biotech investing. With these ethics, companies can continue to gain high revenues with low associated risks. The company’s own successes using these same set of values serves as a shining example.

Dr. Rosenwald has been involved with these processes for many years. He has been a biotechnology entrepreneur on Wall Street for over 17 years. He has also been actively engaged with founding and recapitalizing a number of public and private biotech and life sciences companies. He has earned a B.S. in Finance and an M.D. from Pennsylvania State University and the Temple University School of Medicine respectively.

His experience also extends to managing billion-dollar funds for healthcare and biotech investment. The Aries Funds has invested over $1 billion in healthcare under his management while the Orion Fund is completely devoted to private biotech investments, mainly PIPEs.

The basis of OpusPoint’s foundation is to create and sustain a vast network of life science and healthcare groups that uphold standards of integrity and honesty in their work. This mold is something quite rare today where companies often engage in unethical practices for the purpose of gaining more profit.

OpusPoint Partners will be a different kind of company. It will be a company firmly committed to maintaining fairness and ethics in business dealings as well as in the actual testing, manufacture and investigation of drugs.

Following the guidance of Michael Weiss and Dr. Lindsay Rosenwald, OpusPoint Partners has a bright path ahead. With a leadership built upon so much experience and expertise, it is not hard to see that the company will play a key role in the groundbreaking changes to come in medicine and healthcare.

Trying to change what have been the accepted standards in medicine for years will take costly time and energy. It will take money and a very keen dedication to ethics to resist the temptation of choices that may promise higher profit but that have little moral value.

Dr. Rosenwald, though, thinks that it can be done. He uses the company as an example – it has already exceeded its goals by helping to finance over 20 companies in less than two years. It is certain that with the use of the right practices and procedures, there will be very high returns in the worlds of drug research and finance.

Dr. Lindsay Rosenwald is part of the Republican Jewish Coalition Board of Directors. He has also made close alliances to leaders of the biotechnology financing sector. OpusPoint Partners will enjoy a prosperous future with Dr. Rosenwald as its leader.

Dr. Lindsay Rosenwald and Michael S. Weiss established OpusPoint Partners in 2009. Passionate about biotechnology, the two men have founded several biotech companies together over the years. Rosenwald and Weiss carry more than 40 years of experience under their belts in the fields of life science and biotech investing.

Cougar Biotechnology Inc. is yet another company established by Dr. Lindsay Rosenwald. The company, located in Los Angeles, has established a good portfolio conducting research for new cancer drugs. This has gained the company some attention from researchers and investors. One drug can possibly treat late prostate cancer and on July 10, 2009, Cougar Biotech Labs was sold to Johnson & Johnson for close to one billion dollars.

OpusPoint Partners and Lindsay Rosenwald are devoted to establishing viable partnerships with the biotechnology and investment communities. Keeping integrity amongst relations is one key way of doing this, by remaining open and making honest investments. Leaders of the industry and companies must all recognize the importance of this practice to the strength of their relationships.

Lindsay Rosenwald and OpusPoint Partners are coming together with several researchers, investors and corporations that can join together in providing the world with breakthrough treatments to disease. While lending support to emerging companies and their goals, Dr. Lindsay Rosenwald and OpusPoint Partners will join forces in finding the best research companies on the brink of developing medical innovations.

Dr. Lindsay Rosenwald and OpusPoint Partners aim to challenge the current confines of investing in biotechnology. They are aiming for higher goals in investing and are challenging biotech companies to apply better ethical standards to business and production. OpusPoint Partners is an example of how it is possible to gain attractive rewards without high risks by employing well-rounded practices.

Dr. Rosenwald has had plenty of experience with these ideas. He has been on Wall Street for more than 17 years as a biotechnology entrepreneur. He has also been a key person in the development and recapitalization of several public and private biotech and life sciences companies. He holds a B.S. degree in Finance from Pennsylvania State University and obtained his M.D. from the Temple University School of Medicine.

He also has expertise in financial management of large investment funds. He managed billions of dollars in The Aries Funds (1994 to 2007) and the Orion Fund (2002 to 2006). In the first case, funds have been used to invest in healthcare; in the second case investment has been directed totally to biotechnology, specifically PIPEs.

The founding goal of OpusPoint Partners is to establish a sturdy alliance of partnerships in healthcare and life science that have the same ideals of ethical practice. In the current market, it may be hard to find business leaders who will maintain ethical integrity in their aims for positive clinical outcomes and higher profit.

This is one area where OpusPoint Partners will make a difference. The company has proven its commitments to its shareholders and has also shown its dedication to uphold high principles in drug testing, manufacturing and investigating.

Under the leadership of Michael Weiss and Dr. Lindsay Rosenwald, OpusPoint Partners has a successful future ahead. The combined expertise and experience of both men will help to guide the company in selecting innovative options in healthcare and medicine.

But changing age-old practice in medicine and healthcare will take time, money and great commitment. Trying to keep the ethical standard at a high level will require very strong dedication.

Dr. Rosenwald has no doubts this can be done. OpusPoint Partners, for example, has made very strong strides forward in a short period of time. In less than two years, they were able to financially assist more than 20 companies, proving that using better approaches can certainly yield rewards in the area of drug research and financing.

Dr. Lindsay Rosenwald is a member of the Board of Directors of the Republican Jewish Coalition. In addition, he has close relationships with the biotechnology financing sector. OpusPoint Partners will have a successful development under his direction.

At OpusPoint Partners,we have a vision for an amazing future for the life science and healthcare industry. We believe in that vision so strongly that we are investingmoney and time to advance life sciences and biotechnology. We also believe in a strong, healthy future for human kind. With proper funding and research, we know that the quality of healthcare can be catapulted to a new and more effective level.

A Vision for the Future of Healthcare
With this vision in mind, Michael S. Weiss and Dr. LindsayRosenwald created OpusPoint Partners in 2009. These men have over 40 years of combined experience in the fields of healthcare, life sciences and biotechnology investing. Both are creative thinkers who have founded a number of biotech companies over the years.

Dr. Lindsay A. Rosenwaldhas most recently founded Cougar Biotechnology Inc.,which is a Los Angeles-based firm that focuses on the field of oncology. Cougar’s oncology portfolio includes some promising experimental drugs effective in treatingnumerousforms of cancer. One of those in particular has drawn the interests of researchers and investors. It has proven to work well at treating late-stage prostate cancer. Dr. Lindsay Rosenwald negotiated a deal with Johnson & Johnson for Cougar Biotech Labs at a price of approximately one billion dollars in July of 2009.

Achieving the Objectives
The objective of Lindsay Rosenwald and OpusPoint Partners is twofold: to move forward withintegrity in achieving long-term goals and short-termgains, and to build solid relationships in both the world of investing and biotechnology. By establishing strong relationships withother industry leaders who share similar values, they believe that these goals and objectives can be obtained without the sacrifice of their principles and standards.

For OpusPoint Partners, honest investing with full and open disclosure is more than just good business. This is a way of life.They currently work with a wide range of corporations to create a team approach to supporting emerging new businesses in an effort to reach critical goals. Dr. Lindsay Rosenwald and OpusPoint Partners have made a genuine commitment to discover and invest in innovative technologies in the fields of life sciences and healthcare.These pioneers of research and investment believe in a better future for us all; a future where diseases are diagnosed and treated by more effective methods.
At OpusPoint Partners, Dr. Lindsay Rosenwald, his business partners and colleagues, believe in a world where people’s lives and health are greatly improved. They believe in creating a future where mankind achieves a much stronger quality of life. Through thisunique vision they are making a true difference in theirworld. In order to attain this dream of a better tomorrow for us all, their journey often involves providing advisory services to start-up businesses. Sometimes it requires investing in publicly-traded companies.

Raising the Bar
Dr. Lindsay Rosenwald and OpusPoint Partners, is working to raise the bar for investors. Their efforts include advising emerging biotechnical research facilities. They believe that a strong moral compass along with sound business principles can significantly minimize risks and thereby maximize returns for investors and so far, this unique formula is proving to be successful.

For the past 17 years, Dr. Rosenwald has been a well-respected Wall Street biotechnology entrepreneur. His business ethics have not gone unnoticed. He has, in fact, been instrumental in the founding and re-capitalization of dozens of private and public biotechnology and life-sciences companies. He earned his M.D. from the Temple University School of Medicine and his B.S. in Finance from Pennsylvania State University.

An Innovative Business Philosophy
During his impressive twenty-year career, Dr. Lindsay Rosenwald has founded over fifty companies and managed the Aries Funds from 1994 through 2007 with peak assets under his management in 2000 of over $1BB dedicated to healthcare investments. During the years of 2002 through 2006, he also managed the Orion Fund, which was a committed capital fund dedicated to private investments in biotechnology, in particular PIPEs.

The philosophy behind OpusPoint Partners will be to build a successful life science and healthcare network that plays fair and does not take short cuts to reach its goals. Dr. Rosenwald and his associates know that the world we currently live in often provides too many opportunities for business leaders to use less than ethical tactics to try to manipulate outcomes of clinical trials and hence increase quarterly earnings.
OpusPoint Partners is a uniqueenterprise that continually reinforces its commitment to its employees and investors. Their promise is to deal fairly in all aspects of experimental drug trials. In the investigation and manufacture of experimental drugs, they are resolute about these vows.

The Benefits of Making the World a Better Place
The future of OpusPoint Partners remains highly promising with Michael S. Weiss and Dr. Lindsay Rosenwald as its founders. They are utilizing their expertise in the fields of medicine and investments to effect some very real changes in the way diseases are diagnosed. They believe that the treatment of patients can be transformed.

But revolutionizing these age-old medicaland healthcare techniques and procedures is no small task, nor is it for the faint of heart. In order to effect changes on such a grand scale requires commitment; it requires time and money. It also involves a strong resolve to work hard within the ethical boundaries that other drug research companies may have discarded in favor of better profits.

Dr. Rosenwaldunderscoresthe fact that over the past few years, projected goals have already been surpassed. By applying best practices and processes, OpusPoint Partners moves ahead earning superior, risk-adjusted returns and helpingto finance and support more than 20 companies in the past two years alone. This achievement is marked by a continuing commitment to the financial world and the world of drug research.

Credentials and Lifetime Achievements
Dr. LindsayRosenwald is currently a member of the Board of Directors at the Republican Jewish Coalition. He is one of the most broadly-informed and well-connected individuals in the biotechnology finance sector.The future of OpusPoint Partners looks very promising with Dr. Rosenwald as its vanguard.

As with alllofty visionssuchas this, itwill take immense commitment from quality entrepreneurs to accomplish. Michael S. Weiss and Dr. Lindsay Rosenwald created OpusPoint Partners in 2009 with the idea of combining their 40 years of experience and business acumen working toward revolutionizing the fields of healthcare, life sciences and biotechnology investing. Both these men are well equipped to do this job and have already founded a number of biotech companies over the years.

With so much at stake, OpusPoint Partners along with Dr. Lindsay Rosenwald, is working toward making those leaps to advance and even transform the world of life sciences and biotechnology investing. Rosenwald, along with his team at OpusPoint, believe in a future where mankind significantly improves the quality of healthcare, as well as healthcare investing.

Advancements in the Future of Healthcare
Recently, Dr. Lindsay A. Rosenwaldfounded Cougar Biotechnology Inc. This Los Angeles-based company focuses on the field of oncology. Their oncology portfolio includes some very promising experimental drugs, which are proving to be effective in treatingnumerousforms of cancer.

One in particular has caused some excitement and drawn the interests of researchers and investors. It is a new drug that has been proven to work well at treating late-stage prostate cancer. In July of 2009, Dr. Lindsay Rosenwaldwas able to negotiate a deal with Johnson & Johnson for Cougar Biotech Labs at a price of approximately one billion dollars.

Realizing the Objectives
Lindsay Rosenwald and OpusPoint Partners believe they can continue to move forward with projects like these that alter healthcare significantly and produce results for the greater good of mankind. They achieve these goals with integrity, building solid relationships in both the world of investing and biotechnology.

Establishing robust relationships withother industry leaders who share similar values is a hallmark of the business strategy of both Dr. Lindsay Rosenwald and OpusPoint Partners. They believe in reaching goals and objectives through honesty, integrity and hard work. Their success has proven that you can obtain these objectives without the sacrifice ofprinciples and standards. Honest investing with full and open disclosure is more than just good business for OpusPoint Partners. This is the ideology they live by.

Creating New Partnerships for a Better Tomorrow
Dr. Lindsay Rosenwald and OpusPoint Partners currently work with a wide range of businesses and organizations to create a team approach for thesupport of emerging new businesses. They are making great strides toward building a powerful network of like-minded individuals who all possess a genuine commitment to discover and invest in innovative technologies in the fields of life sciences and healthcare.

With pioneers such as these in the areas of research and investment, you can be sure that thefuture of healthcare and life sciences will continue to flourish. These days, the medical field is well-aware of its need for diseases of all types to be diagnosed and treated by more effective methods. At OpusPoint Partners, Dr. Lindsay Rosenwald, his business partners and colleagues, know that the dream can become a reality with hard work and dedication.

The dream of a better tomorrow continues to be the fuel that fires this vision of a much stronger quality of life for us all. And thisunique vision of making a true difference in the world has become a driving force for Dr. Lindsay Rosenwald and OpusPoint Partners. History shows that dreams like this always take time, money and hard work, plus dedication from those involved.

Raising the Bar for Investors
Over the course of this journey, Dr. Lindsay Rosenwald and OpusPoint Partners must oftenprovide advisory services to start-up businesses. At times they also must invest in publicly-traded companies in order to move the vision forward.

One of their key objectives is to raise the bar for all investors. Whether working in the advisory capacity with emerging biotechnical research facilities or actually investing, OpusPoint followsa strong moral compass.With sound business principleslike these, the risks can be significantly minimizedand the returns for investors maximized. This uniqueformula has proven successful beyond anyone’s wildest dreams.

Utilizing Ethical Business Practices
The philosophy behind OpusPoint Partners is to build a positive and effective life science and healthcare network that plays fair and won’t take short cuts to reach its goals. Dr. Rosenwaldknows from experience, that today’s world often provides many opportunities for business leaders to use less than ethical tactics to try and manipulate outcomes of clinical trials with an eye toward greaterquarterly earnings. Does the end justify the means?

At OpusPoint Partners, the answer is a resounding no! This unique enterprise continually reinforces its commitment to its employees and investors to conduct business with higher standards than many of days gone by. In the investigation and manufacture of experimental drugs, they are resolute about this commitment to honest, above-board business dealings.

A Long and Fruitful Career
The future of OpusPoint Partners remains highly promising with Michael S. Weiss and Dr. Lindsay Rosenwald as its founders. They are utilizing their expertise in the fields of medicine and investments to effect some very real changes in the way diseases are diagnosed. They believe that the treatment of patients can be transformed.

Dr. Rosenwald, a well-respected Wall Street biotechnology entrepreneur, has worked for the past 17 years utilizing strong business ethics in the founding and re-capitalization of dozens of private and public biotechnology and life-sciences companies. He earned his M.D. from the Temple University School of Medicine and his B.S. in Finance from Pennsylvania State University.

Throughout an impressive twenty-year career, Dr. Lindsay Rosenwald has established over fifty companies. He also managed the Aries Funds from 1994 through 2007 with peak assets under his management in 2000 of over $1BB dedicated to healthcare investments. From 2002 to 2006, hemanaged the Orion Fund, which was a committed capital fund dedicated to private investments in biotechnology, in particular PIPEs.

Dr. Lindsay Rosenwald is currently a member of the Board of Directors at the Republican Jewish Coalition. He is one of the most broadly-informed and well-connected individuals in the biotechnology finance sector. The future ofOpusPoint Partners indeed looks promising with Dr. Rosenwald at its helm.

Although Cougar Biotechnology has no approved products distributed on the market yet, it has a significant impact on the development of novel compounds for the treatment of oncology diseases, including castrate-resistant prostate cancer (also known as metastatic advanced prostate cancer). The lead oncology compound by the company is abiraterone acetate, which recently entered into the second Phase 3 trial.

The data analysis of the Phase II study as well as the safety profile of abiraterone acetate in both patients before and after chemotherapy and anti-hormonal therapy produced rather satisfactory results. If FDA approves the drug, the sales could skyrocket to about $500 million a year. In addition to prostate cancer, Lindsay Rosenwald and BioScience’s analysts recommend Cougar to test abiraterone for advanced breast cancer.

Due to safety concerns and generic competition, some compounds owned and distributed by Johnson & Johnson experience declining sales. Taking the current situation in mind, the acquisition of Cougar Biotechnology and investments by Lindsay Rosenwald, would definitely add some value. In recent times, J&J focused on oncology issues and abiraterone acetate has a very high potential that may deliver J&J’s products to the oncology market worldwide. Analysts believe that peak annual sales of abiraterone may reach $1 billion and make the drug number one choice in the battle against advanced prostate cancer.

Strong financial background, backed by Lindsay Rosenwald’s investments and a diversity of the products offered by Johnson & Johnson will help the company as well as local economy to overcome such a long economic downturn.

Dr. Lindsay Rosenwald is not only known for his founding of these breakthrough biotechnology companies, but for his giving to make possible even more breakthroughs. He is a very active philanthropist distributing his giving among many venues. His Rosenwald Foundation helps by donating to institutions that educate and do research in the biotechnology and pharmaceutical fields.

Dr. Rosenwald is the current director of several other companies both privately owned and public. These include Neose Technologies Inc., Interneuron Pharmaceuticals Inc., and Keryx Inc. In addition to these roles he also holds  positions as a member of the board of directors for the Jewish Republican Coalition as well as having a seat on the Columbia-Presbyterian Health Sciences Advisory Council.  The Jewish Republican Coalition aims to connect the Jewish population in America with the Republican officeholders so that there will be a greater understanding and working together between them. His advisory seat enables Dr. Rosenwald to help Columbia University College of Physicians and Surgeons with his input in important decisions. Dr. Rosenwald is able to partake in very influential and important issues concerning peoples health and welfare by the many ways he gives to society.

In quest for his lifelong dream, Rosenwald entered Temple University’s University of Medicine. After graduating from Temple University in 1983, he began an internship at Abington Hospital before starting his own private practice. After filling out his internship, he worked as a health-care professional in his very own practice for 2.5 years. Even though he cherished being a medical doctor, Rosenwald preferred a career where he could blend his two loves – medical science and business enterprise.

www.youtube.com/watch?v=H2NaRLw5mE0

Rosenwald quit his private practice in 1986 to go to Wall Street where he took on a position as a Physician / Analyst, an extremely exclusive position with just a few people doing it at that time. Despite the belief that doctors don’t make good investors, Dr Rosenwald excelled at this position. He had a passion for improving investment finance open to the health care sector and that is primarily why he worked there. People admired him and respected his opinions and knowledge. Even though he missed treating individuals, he recognized this was exactly where he belonged. During this time, he also worked for DH Blair and Company, a private investment organization, as the managing director of corporate finance. Over time, he left D.H. Blair and Company to pay attention to a new venture and firm.

Over time, he has broadened this company by starting new companies and attaining control of other biotech companies. The organization has financed more than two dozen companies within the last three years. He creates these companies by concentrating on the growth of both the corporate and biotechnology portions. All of these firms are separate entities, but interact to support one another. The firms that Rosenwald handles have licensed or acquired over a hundred experimental stage drugs.

One of the most notable accomplishments for Lindsay Rosenwald is setting the record for the speediest acceptance of a new drug to market. In merely thirty months, Arsenic Trioxide was created and approved by the FDA for the treatment of a deadly form of leukemia. This drug has been in the marketplace around the world for over ten years and has saved and prolonged 1000s of lives.

Rosenwald has created really groundbreaking companies one of his companies sold to J&J for more than One Billion Dollars even though they only had 1 drug with phase 2 data. He has also founded the very first publicly traded stem cell company, gene therapy company, and cancer vaccine company. As Rosenwald as the leader, his firms have created probably the most valuable and groundbreaking drug treatments of the 21st century. To add to his achievements he comes up with the very first successful medicine to aid those who are obese.

One of the reasons that Rosenwald’s companies have been profitable is that he hires PhDs, MDs, MBAs, and other experts to serve as his senior level professionals. These people usually have experience in business, however they also tend to possess vast knowledge in the medical community. They are driven to produce new drugs as soon as possible. Some of these medicines have the possibility to change the way we look at medical care entirely today. He has also created the Rosenwald Foundation that has contributed millions of dollars to health care and science instruction to help create the future of medicine.

Lindsay Rosenwald has built his business by constantly looking towards the future and now is no different. He speculates that over the next 20 years the biotech industry will continue to enlarge exponentially. Rosenwald predicts that major biotech breakthroughs of the future will come from smaller, startup biotech companies instead of the massive biotech firms we see these days. He feels the two most pressing problems we face today are heart disease and cancer.

Money Central is MSN’s online resource for all things financial. Whether you’re looking for information about taxes, investments, or how to manage your personal finances, this is a great resource to reference. In a 2003 article by Michael Bush, Lindsay Rosenwald was listed the number one corporate investor.  Praised for his investments in biotech companies such as Cell Therapeutics and Neose Technologies which have led to up to 280% gains in the course of six months, he is named the “top all-star” of corporate insiders.

The New York Times is one of the most famous newspapers in all the US. Even over twenty years ago, they recognized the business intellect of Dr. Lindsay Rosenwald. The article details Rosenwald’s collegiate background and how he excelled in economics and finance, yet pursued his lifelong dream of being a doctor. After a few years of private medical practice, he has combined these two areas of expertise to discovering and investing in breaking edge medical and biotech companies, defying the stereotype that doctors cannot be good investors.

Temple Times is the school news letter of Lindsay Rosenwald’s alma mater, Temple University in Philadelphia. Naming Rosenwald as the “specialist to see if your hedge fund is ailing”, it focuses in on his business success as an entrepreneur that started as a doctor. As the founder and owner, the business has expanded to have offices on three different continents.

His initial step in completing his dream was to get accepted to a medical school, which he did, and started to attend Temple University. After finishing his studies at Temple, he was accepted into an internship at Abington medical center. He worked as a medical doctor in his practice for 2 . 5 years. Although he liked practicing medicine Dr. Lindsay Rosenwald felt as if something was lacking. He made the decision he needed to incorporate his 2 pursuits, business and medicine, and locate a career that would let him peruse those passions.

Rosenwald left his private practice in 1986 to head to Wall Street where he took on a position as a Physician / Analyst, a really exclusive position with only a few people doing it at that time. Despite the stereotype that doctors don’t make good investors, Dr Rosenwald excelled at this placement. He had an eagerness for growing investment capital available to the health care sector and that’s mainly why he worked there. He received great respect in his brand new position, and even though he missed his old private practice, he recognized this is where he actually belonged. He also worked for an exclusive investment firm, DH Blair Co as the Managing Director of Finance, but left after a few years to concentrate on a new venture.

Rosenwald made it profitable by acquiring other biotech organizations and making them a part of his portfolio. The business has financed more than two dozen companies within the last three years. He creates these firms by focusing on the growth of both the corporate and biotechnology portions.  All of these companies are separate entities, but work together to support one another. The businesses that Lindsay Rosenwald handles have licensed or acquired over one hundred experimental stage treatments.

Perhaps one of Dr Rosenwald’s finest accomplishments is that he set the record for the quickest development of a drug. In a little over 2 years, Arsenic Trioxide was researched, tested, approved and delivered to market for managing the leukemia disease. It can be credited with saving thousands of lives in the decade it has been on the market.

Rosenwald has been revolutionary with the businesses he has created. In one of the very best reverse takeovers of them all, his firm, Cougar Biotechnology, sold for over $1 billion to Johnson and Johnson, in spite of only having an individual drug with phase two clinical data. He is also the reason for bringing a stem cell business, a cancer vaccine business, and a gene treatment company all to market. As Lindsay Rosenwald as the director, his companies have created many of the most valuable and groundbreaking drugs of the 21st century. To add to his accomplishments he came up with the very first successful medicine to help those who are obese.

One of the reasons that Rosenwald’s companies have been prosperous is that he hires PhDs, MDs, MBAs, and other specialists to function as his senior level professionals. These people often have qualification in business, but they additionally tend to have vast knowledge in the healthcare community. They attempt to produce new medications with great focus and efficiency. These companies are blazing the trail of new medicines and treatment options that will change the concept of medicine.

Lindsay Rosenwald has built his business by regularly looking towards the future and now is no exclusion. Dr Rosenwald believes that there will probably continue to be rapid growth within the biotechnology sector within the subsequent twenty years. At the rate it is developing, this growth will be exponential. According to Rosenwald, upcoming medical breakthroughs will come via small biotech companies that are concentrated in on generating just a few products, as opposed to a giant biotech company that has many tasks in work at once. Rosenwald believes that emphasis ought to now be placed on discovering remedies for 2 of society’s greatest healthcare dangers – heart disease and cancer.